Comera Life Sciences IPO: What You Need to Know

By Kirsteen Mackay


Comera Life Sciences Holdings (NASDAQ: CMRA) $159m IPO. 

Comera Life Sciences IPO

Providing the freedom of self-injectable care to patients who rely on intravenous (“IV”) biologics.

Comera Life Sciences Holdings (NASDAQ: CMRA) is going public via IPO in a $159m deal.

Millions of patients with significant diseases spend day after day at an infusion center with an IV in their arm. Comera Life Sciences wants to offer an alternative, empowering patients to administer their own medicine via injection.

What is Comera Life Sciences?

Comera Life Sciences Holdings, Inc is a biotech company developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience.

The company is applying a deep knowledge of formulation science and technology to transform essential biologic medicines from intravenous to subcutaneous forms.

This approach aims to provide patients with the freedom of self-injectable care, reduce institutional dependency, and put patients at the center of their treatment regimen. 

When will Comera Life Sciences go public?

On 20 May, Comera Life Sciences announced the completion of its business combination with OTR Acquisition Corp. (NASDAQ: OTRAU, OTRA and OTRAW,) a publicly traded special purpose acquisition company (SPAC).

OTR’s shareholders approved the transaction on 10 May 2022. Comera’s shareholders previously approved the transaction.

Jeff Hackman, CEO and Chairman of Comera, said:

Transforming the delivery of biologics from intravenous to subcutaneous forms has the potential to reduce healthcare costs and improve patient quality of life by offering patients self-injectable treatments that support greater independence.

With multiple pharmaceutical partnerships already in place, we are executing on our long-term strategy to leverage our SQore™ platform. 

Nicholas J. Singer, Chairman and Chief Executive Officer of OTR, said:

There is tremendous opportunity in this multi-billion dollar market to transform the patient treatment experience.

Recent Milestones

Last week, Comera entered into a research collaboration with a top 10 global pharmaceutical company and developer of medicines across oncology, hematology, immunology, and other therapeutic areas.

Under the terms of the agreement, Comera will utilize its proprietary SQore™ formulation platform to develop a subcutaneous formulation of the partner’s currently marketed medicine.

Jeff Hackman, CEO and Chairman of Comera, said:

Our second announced collaboration this year is a critical milestone in our long-term strategy to partner with top-tier pharma companies and leverage our SQore platform to develop subcutaneous formulations to improve access and patient use for much-needed medications

We look forward to building upon the success of our partner’s biologic therapy. Subcutaneous dosing offers the possibility of self-care, less invasiveness, shorter treatment times, healthcare savings and other significant advantages over current forms of intravenous administration.

The financial terms of the collaboration were not disclosed.

This follows Comera’s April announcement of a research collaboration with Intas Pharmaceuticals to develop a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience.

About OTR Acquisition Corp.

OTR Acquisition Corp. (NASDAQ: OTRA) was a $107m special purpose acquisition company (SPAC) formed to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. OTR was sponsored by OTR Acquisition Sponsor LLC, an affiliate of investor and entrepreneur Nicholas J. Singer and Purchase Capital.

The OTR SPAC team comprises growth-oriented executives with a long track record of value creation across industries, including life sciences, bringing over 100 years of combined investing and operating experience to this business combination.


In this article:


Author: Kirsteen Mackay

This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.

Kirsteen Mackay does not hold any position in the stock(s) and/or financial instrument(s) mentioned in the above article.

Kirsteen Mackay has not been paid to produce this piece by the company or companies mentioned above.

Digitonic Ltd, the owner of, does not hold a position or positions in the stock(s) and/or financial instrument(s) mentioned in the above article.

Digitonic Ltd, the owner of, has not been paid for the production of this piece by the company or companies mentioned above.

Sign up for VTM Updates

Form submitted successfully!